Lidan Yi

Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis

Qiao Liu, Xia Luo, Liubao Peng et al. · Clinical Drug Investigation · 2019 · 47 citations · Full text

First-Line Chemo-Immunotherapy for Extensive-Stage Small-Cell Lung Cancer: A United States-Based Cost-Effectiveness Analysis

Qiao Liu, Xia Luo, Lidan Yi et al. · Frontiers in Oncology · 2021 · 36 citations · Full text

Cost-Effectiveness Analysis of Adding Palbociclib as a Second-Line Endocrine Therapy for HR+/HER2– Metastatic Breast Cancer From the US and Chinese Perspectives

Yingjie Zhang, Xiaohui Zeng, Haijun Deng et al. · Clinical Therapeutics · 2019 · 33 citations

Breast Oncology, Cost-effectiveness Analysis, Medicine +8

First-Line Atezolizumab for Metastatic NSCLC with High PD-L1 Expression: A United States-Based Cost-Effectiveness Analysis

Peng Ye, Xiaohui Zeng, Liubao Peng et al. · Advances in Therapy · 2021 · 31 citations

Oncology, High Pd-l1 Expression, Pharmacology +7

Economic Outcomes of Maintenance Gefitinib for Locally Advanced/Metastatic Non-Small-Cell Lung Cancer with Unknown EGFR Mutations: A Semi-Markov Model Analysis

Xiaohui Zeng, Jianhe Li, Liubao Peng et al. · PLoS ONE · 2014 · 28 citations · Full text